At SynCardia Systems, LLC, we have a very special mission: to give end-stage heart failure patients the priceless gift of more time. More time with their families and friends, more time outside the hospital enjoying life and more time to receive a heart transplant.
Headquartered in Tucson, Arizona, SynCardia was founded in 2001 by renowned cardiothoracic surgeon Jack G. Copeland, MD; biomedical engineer Richard G. Smith, MSEE, CCE; and interventional cardiologist Marvin J. Slepian, MD. Today, SynCardia is the sole manufacturer and provider of the world’s only commercially approved total artificial heart. In clinical use for more than 35 years, the SynCardia temporary Total Artificial Heart (TAH) is the most widely used and extensively studied total artificial heart in the world.
By partnering with, training and supporting healthcare teams at more than 140 transplant hospitals and heart failure programs in more than 20 countries, SynCardia helps create better outcomes for critically ill adults and adolescents whose best chance of survival is total heart replacement. When a donor heart isn’t available or isn’t an option, SynCardia provides a new heart without the wait for patients at risk of dying or becoming too sick to transplant because of end-stage biventricular failure.
The SynCardia team is passionate about saving lives and dedicated to responsiveness, teamwork, safety, reliability and innovation. We believe that no one should die waiting for a matching donor heart. We also believe that a hospital isn’t a home; that for optimal patient quality of life, the ability to discharge stable patients home to enjoy a near-normal quality of life is vital. As a result, we are committed to advancing the treatment of end-stage biventricular failure to help improve patient care, quality of life and long-term outcomes.
SynCardia is proud to be a partner of Ava’s Heart and to support the selfless work they do to provide for patients financial and other needs as they navigate the transplant journey